# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce field of invention
- describe head and neck squamous cell carcinoma
- discuss limitations of current treatments
- motivate need for new antisense agents

## SUMMARY OF THE INVENTION

- introduce GPNA antisense agents

## DESCRIPTION OF THE PREFERRED EMBODIMENT(S)

- describe GPNA backbone
- explain PTD positioning
- discuss PNA and PTD properties
- introduce EGFRAS GPNA oligonucleotides
- describe EGFR inhibition methods
- discuss receptor downmodulation
- explain antisense gene therapy
- describe limitations of prior art antisense oligonucleotides
- introduce GPNA oligonucleotides with internally linked D-arginine side chains
- describe synthesis of GPNA monomers
- explain GPNA oligomer synthesis
- describe characterization of EGFRAS GPNA
- introduce alternative GPNA sequences
- discuss distribution of guanidinium residues

### GRCARTCRGCRTGRCTRCCRCCRG (SEQ ID NO:6);

- introduce alternative GPNA sequence

### CRCTRCCRGTRGGRTCRATRGCRTCRC (SEQ ID NO:8),

- introduce alternative GPNA sequence

### CRGGRAGRGGRTCRGCRATRCGRCTRG (SEQ ID NO:10).

- introduce alternative GPNA sequence
- conclude GPNA sequence discussion

## Example 1

- introduce in vivo antitumor efficacy study
- describe study methodology
- present study results

## Example 2

- introduce systemic delivery study

